Wiesloch, Germany

Yingzi Ge


 

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: The Innovative Contributions of Yingzi Ge in Cancer Research

Introduction

Yingzi Ge, an accomplished inventor based in Wiesloch, Germany, has made significant strides in the field of cancer research. With three patents to her name, her work primarily focuses on the development of innovative antibody therapies aimed at treating various cancers and related disorders.

Latest Patents

Yingzi Ge's latest patents center around "Anti-CEACAM6 antibodies and uses thereof." This invention provides recombinant antigen-binding regions and antibodies that specifically target the human CEACAM6, a vital protein involved in cell adhesion and signaling, particularly in the context of cancer. The unique aspect of these antibodies is their reduced cross-reactivity with similar proteins such as human CEACAM1, CEACAM3, and CEACAM5. Additionally, the patents detail methods for generating such antibodies, along with nucleic acid sequences encoding them, vectors containing these sequences, and pharmaceutical compositions ready for clinical application. The implications of her work are profound, as these antibodies can potentially treat cancer and other conditions associated with CEACAM6 expression.

Career Highlights

Ge has contributed her expertise to prominent institutions, including the Deutsches Krebsforschungszentrum (German Cancer Research Center) and Bayer Pharma AG. Her work at these organizations has not only fostered her research skills but has also solidified her role as a pivotal figure in the biotechnology field.

Collaborations

Throughout her career, Yingzi Ge has collaborated with esteemed colleagues such as Jörg Willuda and Uwe Gritzan. Together, they have contributed to groundbreaking research and the development of innovative therapeutic solutions.

Conclusion

Yingzi Ge's patent contributions and collaborative efforts mark her as a vital innovator in the realm of cancer treatment. Her pioneering work on anti-CEACAM6 antibodies holds immense potential to advance medical therapies and improve patient outcomes, underscoring her significant impact on the field of biomedical innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…